Navigation Links
PARI Granted US Patent for Vortex Holding Chamber
Date:7/21/2009

MIDLOTHIAN, Va., July 21 /PRNewswire/ -- Today, PARI Respiratory Equipment was granted a US Patent for its Vortex Holding Chamber, a unique, non-electrostatic, holding chamber with a one piece, dual-valve system that optimizes patient inhalation and exhalation for more efficient medication delivery with a metered dose inhaler (MDI).

"While metered dose inhalers offer a quick burst of medication, there are a number of problems delivering an effective dose to patients. These include medication waste due to high-speed delivery to the back of the throat and loss of medication due to improper use. The Vortex Holding Chamber does a wonderful job of addressing these issues, in particular for young patients and for any person who has difficulty using an inhaler, by allowing patients to breathe normally while using the one piece, dual-valve system to direct medication flow and a patient's exhalation breaths," said Dr. Welch, co-director of the Allergy and Asthma Medical Group and Research Center in San Diego, and clinical professor at the University of California, San Diego School of Medicine.

"Innovations like the Vortex Holding Chamber truly enhance respiratory care by making therapies easier for patients. We are very pleased that the Vortex Holding Chamber has been granted this US patent, because the Vortex Holding Chamber ensures patients do not have to worry about coordinating their breaths when using a MDI to get an effective treatment. This enhances drug delivery, minimizes drug delivered to the throat, and allows low resistance inhalation and exhalation with the device," added Geoff A. Hunziker, president of PARI Respiratory Equipment.

The Vortex Holding Chamber has a number of unique features. When a patient inhales, the Vortex Holding Chamber directs airflow through a medication holding chamber and into the patient. During exhalation, airflow is directed out of the device while reducing medication loss. Because it is metal, the Vortex Holding Chamber's non-electrostatic walls do not attract medication as plastic devices do, thereby reducing medication loss in the holding chamber. It also features a cyclonic, inspiratory flow pattern that further enhances aerosol delivery. Patients can breathe normally while the Vortex Holding Chamber's one piece, dual-valve system enhances medication delivery and reduce drug waste.

About PARI Respiratory Equipment, Inc.

PARI is a leading worldwide developer and manufacturer of fast and efficient aerosol delivery systems for patients with asthma, chronic lung disease, and cystic fibrosis. PARI's worldwide vision is to improve the lives of those affected by respiratory diseases and those who care for them.

Maker of the world's leading breath-enhanced reusable nebulizer, the PARI LC PLUS, and the new PARI LC Sprint nebulizer line, PARI also manufactures the award winning PARI TREK S compact compressor, Bubbles the Fish II aerosol mask, and durable PARI PRONEB Ultra II. Its Vortex Holding Chamber's anti-static, valved holding chamber improves the aerosol deposition of metered dose inhalers (MDIs). PARI's North American headquarters is in Midlothian, VA with worldwide headquarters in Starnberg, Germany. Online at www.Pari.com

Additional information is available by contacting Kirsten Ayars at 805-845-5682 or Ashley Weigand at 804-253-7274 x711.


'/>"/>
SOURCE PARI Respiratory Equipment, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. PREOS(R) Granted U.S. Orphan Drug Status for Treatment of Hypoparathyroidism
2. Abbott Broadens Use of i-STAT Handheld Blood Analyzer with CLIA Waiver Granted by FDA for CHEM8+ Test Cartridge
3. USC granted $8.4 million for autism research
4. Aida Granted Additional Anti-Cancer Patent
5. CME LLC Granted Five-Year Full Approval by the American Psychological Association
6. ActiPatch(TM) Granted Market Clearance by the Food & Drug Administration in the Kingdom of Jordan
7. TREANDA New Drug Application for the Treatment of Chronic Lymphocytic Leukemia Granted Priority Review Status by FDA
8. Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
9. Isis Announces ISIS 333611 Granted Orphan Drug Status for Treatment of ALS
10. Phylonix granted broad European patent for transplanting human cells into zebrafish
11. Seven Community Service Organizations Granted Over $60,000 From Delta Dental Of Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... , ... January 17, 2017 , ... A prescription medication ... of the fourth Cradle to Cradle Product Design Challenge , the Cradle ... a series of six circular design challenges scheduled to run through early 2018. The ...
(Date:1/17/2017)... ... January 17, 2017 , ... Wettstein ... to families and business professionals throughout central Colorado, is joining local nonprofit Aurora ... The Aurora Warms The Night organization is committed to breaking the cycle of ...
(Date:1/17/2017)... ... January 17, 2017 , ... Seceon , the ... in real-time, today announced a strategic partnership with TechLab Security, a ... Seceon partners, TechLab Security has become a strategic partner and a value added ...
(Date:1/17/2017)... New York, NY (PRWEB) , ... January 17, ... ... of Inc. Magazine’s fastest-growing private companies and ranked among the top US security ... first Board of Directors. This announcement brings a year-long independent board nomination ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... GRAND RAPIDS, Mich. , Jan. 17, 2017 ... of Richard M. Erwin as Vice ... Catalyst Pharmaceuticals, where he was Executive Director, Clinical Project Management. ... with over 25 years of experience in global ... a string of successful growth-stage clinical operation build-outs ...
(Date:1/17/2017)...  Bayer today announced the appointment of Dr. Carsten ... Americas, comprising the United States , ... . In this role, Dr. Brunn will report to ... of Bayer AG and President of the Pharmaceutical division. ... the pharmaceutical industry and I,m delighted to have him lead ...
(Date:1/16/2017)... 2017 Research and Markets has announced the ... report to their offering. ... Global multiple myeloma drugs market to grow at a ... report covers the present scenario and the growth prospects of the ... size, the report considers the revenue generated from the sales of ...
Breaking Medicine Technology: